You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The firm's assay leverages reverse transcriptase quantitative PCR to amplify two separate regions of the HIV-1 genome to monitor HIV-infected patients.
The Agilent SARS-CoV-2 qRT-PCR Dx kit detects N1 and N2 targets from SARS-CoV-2 RNA isolated and purified from nasopharyngeal swab specimens.
Azova's kit is for use with Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay, an extraction-free, saliva-based COVID test that previously received EUA.
Labs like Biodesix, ARUP, Quest, and Labcorp engaged different strategies to prevent loss of patient samples during recent extreme weather.
A pair of studies published this week present an analysis of a real, large-scale testing pooling effort as well as analyses of how to further improve such strategies.
The firm's quarterly revenues beat estimates. Its full year revenues also beat estimates and were up 10 percent year over year.
Fluidigm's Advanta Dx SARS-CoV-2 RT-PCR assay is an extraction-free saliva-based test to detect nucleic acid from the SARS-CoV-2 virus.
The firm expects to receive a CE mark later this year for its RT-qPCR breast cancer recurrence assay, which characterizes epithelial CTCs by detecting cytokeratin-19 expression.
Some tests that detect multiple SARS-CoV-2 genes are serendipitously signaling new viral variants while still effectively detecting infections.
The US Department of Health and Human Services (HHS) said that it would use Fluidigm's saliva-based molecular SARS-CoV-2 test as part of a federal surge testing program.